Ask AI
ProCE Banner Activity

ISLEND-2: Quality of Life in People With Virologically Suppressed HIV After Switch to Weekly ISL/LEN

Conference Coverage
Slideset

In this assessment of participants in the phase III open-label ISLEND-2 study, investigators used descriptive statistics and validated and de novo questionnaires to evaluate quality of life in persons with virologically suppressed HIV who switched from daily oral standard-of-care ART to once-weekly islatravir/lenacapavir. 

Released: November 13, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions